0QNO.LSE Lonza Group AG

Healthcare Diagnostics & Research London Exchange
479.82 CHF
Close of Nov 3, 2026
452.76 653.20
Market cap
CHF 35.7B
P/E
16.4x
P/B
-
ROE
29.1%
Dividend yield
0.40%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0QNO.LSE undervalued?

Graham number

The Graham number of Lonza Group AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lonza Group AG fundamental analysis

No fundamental analysis for Lonza Group AG yet.

Lonza Group AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manuf…

Full company profile